# 2023 exceptional surveillance of stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NICE guideline NG128)

Surveillance report Published: 10 May 2023

www.nice.org.uk

2023 exceptional surveillance of stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NICE guideline NG128)

# Contents

| S | Surveillance decision                                | 3 |
|---|--|---|
|   | Reasons for the decision                             | 3 |
|   | Reason for the exceptional review                    | 3 |
|   | Methods  | 3 |
|   | Evidence considered for the exceptional review       | 4 |
|   | Information considered when developing the guideline | 6 |
|   | Other relevant NICE guidance                         | 6 |
|   | Equalities   | 6 |
|   | Stakeholder consultation                             | 6 |
|   | Overall decision                                     | 7 |

# Surveillance decision

We will not update recommendation 1.2.3 on carotid imaging in NICE's guideline on stroke and transient ischaemic attack in over 16s.

## Reasons for the decision

An individual patient data (IPD) meta-analysis was highlighted to NICE suggesting that intraplaque haemorrhage (IPH) identified using magnetic resonance imaging (MRI) scans is a strong predictor of future strokes. Although the IPD analysis suggests that IPH is a strong predictor of future stroke, currently there is no evidence of its impact on patient management and outcomes.

However, an ongoing trial which utilises IPH data for risk classification and management decisions on carotid endarterectomy has been identified which may provide further patient outcomes evidence.

Without specific evidence to suggest that patients benefit from IPH data from carotid MRI, the guideline will not be updated at this time. We will continue to monitor the ongoing trial in this area.

## Reason for the exceptional review

We have been asked to review whether the guideline recommendations should be updated based on an IPD meta-analysis suggesting that IPH identified through MRI scans is a strong predictor of future strokes (<u>Schindler et al. 2020</u>).

## Methods

The exceptional surveillance process consisted of:

- Considering the new evidence that triggered the exceptional review.
- Considering the evidence used to develop the guideline.

- Feedback from topic experts. The topic experts provided feedback on the utility of carotid MRI and IPH data within the NHS.
- Considering ongoing trials.
- Assessing the new evidence and information from topic experts' feedback against current recommendations to determine whether to update sections of the guideline, or the whole guideline.
- Considering comments received during consultation and making any necessary changes to the proposal.

## Evidence considered for the exceptional review

We considered an IPD meta-analysis (<u>Schindler et al. 2020</u>), which pooled data from 7 cohort studies. This analysis included 560 patients with symptomatic carotid stenosis and 136 patients with asymptomatic carotid stenosis, with a total of 1,121 observed patient years.

The analysis compared the risk of ipsilateral ischaemic stroke (primary outcome) between patients with and without IPH, adjusted for clinical risk factors. 51.6% of patients with symptomatic carotid stenosis and 29.4% of patients with asymptomatic carotid stenosis had IPH. A total of 66 ipsilateral stroke episodes occurred in these cohorts.

Among patients with symptomatic carotid stenosis, multivariate analysis identified IPH (hazard ratio [HR]: 11.0; 95% confidence interval [CI]: 4.8 to 25.1) and a severe degree (70% to 99%) of stenosis (HR: 3.3; 95% CI: 1.4 to 7.8) as independent predictors of ipsilateral stroke. Annualised event rates of ipsilateral stroke were 9.0% versus 0.7% (<50% stenosis), 18.1% versus 2.1% (50% to 69% stenosis), and 29.3% versus 1.5% (70% to 99% stenosis) in those with IPH versus those without IPH.

#### Topic expert feedback

Five topic experts with a special interest in stroke completed an online questionnaire: 1 professor of neurology, 1 clinical lead for stroke, 1 professor of ageing and stroke medicine; 1 professor of public health and primary care and 1 clinical nurse specialist.

The topic experts suggested that carotid MRI is seldom used for patients with stroke or transient ischaemic attack (TIA) for the following reasons:

2023 exceptional surveillance of stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NICE guideline NG128)

- There are significant access issues. One expert noted that it is only used when consistent or timely access to carotid doppler imaging is unavailable, while another mentioned that it is not available in their local area.
- Although carotid MRI may provide additional information for risk classification in certain patient groups (for example, those with less than 50% carotid artery stenosis), there is currently no evidence that it impacts treatment decisions or outcomes.
- The impact of carotid MRI on patient outcomes remains unclear. Currently, there is no randomised controlled trial (RCT) or test-and-treat trial evidence to suggest that performing urgent surgery on patients identified through this imaging technique is beneficial.

There is no consensus on the usefulness of carotid MRI, and considerations provided suggest that an update is unnecessary for the time being:

- One expert thought that recommendations about carotid MRI could improve service organisation and overall access to imaging services.
- One expert suggested that recommendations to prevent overuse may be helpful, but this is not a priority unless there is widespread use.
- Another expert suggested that no recommendations should be made without further research and evidence being available.

#### Ongoing trials

To our knowledge, no test-and-treat trials have been conducted using IPH or carotid MRI data, nor have any RCTs been conducted where the selection of the patient group is based on IPH findings instead of the NASCET (North American Symptomatic Carotid Endarterectomy Trial) or European Carotid Surgery Trial (ECST) criteria.

The topic experts helped to identify 1 relevant ongoing RCT (<u>ESCT-2</u>). This trial aims to compare the effectiveness of immediate surgery (endarterectomy) in combination with optimised medical treatment versus optimised medical treatment alone for patients with carotid stenosis  $\geq$ 50% who have a low to intermediate risk of stroke. The study hypothesis is that patients treated with optimised medical therapy may no longer require additional carotid revascularisation, as medical therapy has significantly improved since the publication of <u>NASCET</u> in 1999. By utilising IPH data to improve risk prediction of future strokes in patients with carotid stenosis, some patients may be able to avoid undergoing

surgery.

# Information considered when developing the guideline

Carotid imaging was reviewed when the NICE guideline was developed in 2008, but only ultrasound evidence was considered at that time. The selection criteria used for NASCET and ECST criteria indirectly informed recommendation 1.2.3 about carotid imaging and recommendations 1.2.4 to 1.2.6 about urgent carotid endarterectomy.

The use of MRI or other imaging techniques to detect IPH was not considered in the 2019 and 2022 updates.

## Other relevant NICE guidance

There is currently no other NICE guidance in this area.

# Equalities

The topic experts' feedback mentioned potential inequalities related to age and ethnicity.

Concerns have been raised about access for people who live in rural areas. These tend to have smaller district general hospitals, fewer imaging resources, and an older population. As people who had a stroke or TIA are unable to drive and public transport is lacking in rural areas, it is challenging for them to have to travel great distances to attend a clinic or get a scan.

An equalities and health inequalities assessment was completed during this surveillance review. See <u>appendix A</u> for details.

# Stakeholder consultation

We received consultation responses from 5 stakeholders, which included NHS England, 1 professional organisation, 1 patient organisation, 1 local NHS partnership and 1 commercial company.

2023 exceptional surveillance of stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NICE guideline NG128)

See appendix B for stakeholder consultation comments and our responses.

Of the stakeholders, 1 agreed that the guideline should not be updated, 1 did not provide an opinion and 3 disagreed with our proposal. Of the stakeholders who disagreed, 1 had suggested updating an area that is outside the scope of this review. The other 2 stakeholders were concerned that the decision to not update the guideline is due to the difficulty of accessing MRI scans. One stakeholder pointed out that there are ongoing efforts to extend the availability of brain MRI scan for TIA or mild stroke patients, and this in the future could extend the availability to also conduct a carotid MRI for these patients. The other stakeholder stated that MRI access is not a barrier in some areas.

On possible health inequality issues on the use of doppler imaging, 1 stakeholder commented that some patients may feel claustrophobic during MRI scanning, and doppler imaging would be alternative in those situations.

See <u>ensuring that published guidelines are current and accurate in developing NICE</u> <u>guidelines: the manual</u> for more details on our consultation processes.

## **Overall decision**

We will not update recommendation 1.2.3 on carotid imaging in NICE's guideline on stroke and transient ischaemic attack in over 16s.

Although there is evidence that IPH detected using carotid MRI scans can predict stroke risk, there is no conclusive evidence on how this information impacts clinical decision making and patient outcomes. We will monitor the ongoing trial for the impact of IPH data on patient outcomes.

ISBN: 978-1-4731-5184-0